Citations

Clear

3138 citation(s) found for "Smith, AM".

Sex differences in growth in body mass and psychosocial abilities in children in Head Start
Miccoli, Antonela , Smith, Latasha M. , Hansen, Carina , Lynch, Brian , Toussaint, Loren

Mayo Clinic

Early Child Development and Care | March 11, 2022 | Volume: 192 | Issue: 16 | Pages: 2646-2655

10.1080/03004430.2022.2044322 Get It

The Impact of Wearable Breast Pumps on Physicians' Breastfeeding Experience and Success
Colbenson, Gretchen A. , Hoff, Olivia C., Olson, Emily M. , Ducharme‐Smith, Allison

Mayo Clinic

Breastfeeding Medicine | March 10, 2022 | Volume: 17 | Issue: 6 | Pages: 537-543

10.1089/bfm.2021.0266 | PMID 35271350 Get It

Abstract P3-23-05: Evaluation of CDK 4/6 inhibitor practice patterns and institutional versus national adherence to palbociclib laboratory monitoring in breast cancer patients
Taraba, Jodi L. , Swarna, Kavya, Golbach, Allison, Sangaralingham, Lindsey R. , Ruddy, Kathryn J. , Haddad, Tufia C. , Taraba, Jodi L , Golbach, Allison P. , Mara, Kristin C. , Smith, Matthew Raymond , Giridhar, Karthik V.

Mayo Clinic

Cancer Research | March 8, 2022 | Volume: 82 | Issue: 4_Supplement | Pages: P3-23-05-P3-23-05

10.1158/1538-7445.sabcs21-p3-23-05 Get It

Abstract Background: Cyclin dependent kinase (CDK) 4/6 inhibitors (CDK 4/6i) can improve outcomes in ER-positive/HER2-negative (ER+/HER2-) breast cancer. The choice of CDK 4/6i selection and dose depends on clinical context and/or potential side effect of profile of each unique CDK 4/6i. The objective of this study was to evaluate practice patterns in patients initiated on CDK 4/6i and assess adherence to recommended laboratory monitoring in breast cancer patients in both an institutional and national dataset. Methods: The institutional cohort (IC) involved a retrospective chart review of patients newly initiated on palbociclib between May 8, 2018 - June 4, 2019 at Mayo Clinic, Rochester. The national cohort (NC) reviewed medical and pharmacy claims data from the OptumLabs Data Warehouse (OLDW) and included patients who were initiated on palbociclib (P), ribociclib (R) or abemaciclib (A) between February 6, 2015 - September 30, 2019. NC patients were required to have a minimum of 6 months baseline coverage, 6 months coverage after first prescription and Day 1 labs drawn. For both cohorts, patients were ≥18 years old with metastatic ER+/HER2- breast cancer. Data was collected for up to 6 cycles of treatment and included cycle start dates, doses, dates of lab draws and dose changes. Laboratory adherence was defined as a complete blood count being drawn +/- 3 days of the defined timepoint for the IC and +/- 5 days for the NC with a l4-day window for Cycle 1, Day 1 labs. Results: The IC included 81 patients and the NC 2600. In the NC, the most prescribed CDK 4/6i was P (90%), followed by A (6%) and R (4%). Prescription breakdown by geographic region was Midwest (26%), Northeast (14%), South (47%), West (13%). Ethnic breakdown of the group was White (68%), Black (15%), Hispanic (8%), Asian (3%) and unknown (6%). P practice pattern data were available for both the IC and NC, but R and A data in the NC only. In the IC, the initial P dose was 125 mg (95%), 100 mg (1%) and 75 mg (4%). In the NC, P (n=2329) dose was 125 mg (81%), 100 mg (15%) and 75 mg (4%). Dose reductions were common with 25% and 28% of patients requiring one dose reduction and 16% and 9% of patients requiring two dose reductions in the IC and NC, respectively. In NC patients initially treated with P, 5% were subsequently treated with A and 2% with R. In the NC, A (n=163) was initiated at 200 mg (7%), 150 mg (79%), 100 mg (10%) and 50 mg (4%). One dose reduction was required in 25% of patients and 6% required two dose reductions. Of those initially treated with A, 16% were subsequently treated with P and 1% with R. In the NC, R (n=108) was initiated at 600 mg (81%), 400 mg (8%) and 200 mg (11%). One dose reduction was required in 17% of patients and 2% required two dose reductions. Of those initially treated with R, 7% each were subsequently treated with P and 10% with A. Laboratory adherence was assessed for P only. For the IC, a total of 81 patients were included (mean age 61±13 years, 98% female and 95% White). The NC included 2329 patients (mean age 66±12 years, 99% female and 69% White). Laboratory adherence is listed in the table below: Conclusions: P was the most commonly prescribed CDK 4/6i. Dose reductions were less common with R. Adherence to laboratory monitoring was higher in our institutional cohort than in a national administrative claims database. Initiatives to ensure that labs are drawn at recommended timepoints during P therapy will be important for safety. ICNCC1D193%100%C1D1589%61%C2D191%71%C2D1558%55%C3D199%62%C4D190%55%C5D184%53%C6D178%50%C = cycle, D = day. Citation Format: Jodi Taraba, Kavya Swarna, Allison Golbach, Lindsey Sangaralingham, Kathryn Ruddy, Kristin Mara, Matthew Smith, Tufia Haddad, Karthik Giridhar. Evaluation of CDK 4/6 inhibitor practice patterns and institutional versus national adherence to palbociclib laboratory monitoring in breast cancer patients [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P3-23-05.
Clinical Outcomes of Ahmed ClearPath Implantation in Glaucomatous Eyes: A Novel Valveless Glaucoma Drainage Device
Grover, Davinder S. , Kahook, Malik Y., Seibold, Leonard K., Singh, Inder Paul, Ansari, Husam, Butler, Michelle R., Smith, Oluwatosin , Sawhney, Gagan, Tassel, Sarah H. Van, Dorairaj, Syril

Mayo Clinic

Journal of Glaucoma | March 6, 2022 | Volume: 31 | Issue: 5 | Pages: 335-339

10.1097/ijg.0000000000002013 | PMID 35249988 Get It

Précis: Designed with novel features to facilitate implantation and improve safety, the Ahmed ClearPath (ACP) glaucoma drainage device (GDD) provided intraocular pressure (IOP) reduction comparable with other GDDs in eyes with refractory glaucoma in a multicenter retrospective study. Purpose: To present clinical outcomes with a novel valveless GDD (ACP, New World Medical). The 250 and 350 mm2 models feature a contoured plate for optimal globe apposition, anteriorized suture points to facilitate suturing to the globe, and a prethreaded 4-0 polypropylene ripcord suture. Methods: This was a multicenter retrospective analysis of eyes with medically and/or surgically uncontrolled glaucoma implanted with the 250 or 350 mm2 ACP either as a standalone procedure or in combination with other procedures. Pre-, intra-, and postoperative data through 6 months were collected. Results: A total of 104 eyes (100 subjects) received the ACP by 10 US surgeons, 63.5% of which had primary open-angle glaucoma and 62.5% had severe glaucoma. Mean baseline IOP was 26.3 (9.0) mm Hg and mean medication use was 3.9 (1.3). Through 6 months’ follow-up, mean IOP ranged from 13.6 to 16.7 mm Hg and mean medication use from 0.9 to 1.9 medications (P<0.0001 at all timepoints for each outcome measure). At 6 months, mean IOP was 13.7 mm Hg (−13.0 mm Hg, 43.0%, P<0.0001) and mean medication use was 1.9 medications per eye (−2.1, 47.7%, P<0.0001). Common adverse events included anterior chamber inflammation (16.3%), hyphema (15.4%), and hypotony (6.7%). Conclusion: The new ACP appears to be safe and efficacious as a standalone procedure or in combination with other procedures for uncontrolled glaucoma, and may be considered as a GDD option for patients in whom its unique design may facilitate the implantation process.
The spectrum of brachial plexopathy from perineural spread of breast cancer
Jack, Megan M., Smith, Brandon W., Capek, Stepan, Marek, Tomas, Carter, Jodi M., Broski, Stephen M., Amrami, Kimberly K., Spinner, Robert J., Carter, Jodi M. , Marek, Tomáš , Carter, Jodi , Jack, Megan M., Smith, Brandon W., Capek, Stepan, Carter, Jodi M., Broski, Stephen M., Amrami, Kimberly K., Spinner, Robert J.

Mayo Clinic

Journal of Neurosurgery | March 4, 2022 | Volume: 137 | Issue: 5 | Pages: 1368-1377

10.3171/2021.12.jns211882 | PMID 35213832 Get It

OBJECTIVE Perineural spread of breast cancer to the brachial plexus can lead to pain, sensory alterations, and upper-extremity weakness. Although rare, perineural spread is an often-misdiagnosed long-term complication following breast cancer diagnosis. The objective of this study was to critically review the clinical, radiological, and pathological findings of biopsy-proven perineural spread of breast cancer to the brachial plexus. METHODS This is a retrospective study from a single institution in which a total of 19 patients with brachial plexus involvement from perineural spread of breast cancer who underwent fascicular biopsy between 1999 and 2021 were identified. Clinical, radiographic, and pathological data were retrospectively collected. Descriptive statistics were calculated for the cohort. RESULTS The mean age of patients at the time of diagnosis of breast cancer perineural spread was 60.6 ± 11.5 years. The diagnosis of brachial plexopathy due to perineural spread was on average 12 years after the primary diagnosis of breast cancer. There was also a delay in diagnosis due to the rarity of this disease, with a mean time from initial symptom onset to diagnosis of perineural spread of 25 ± 30 months. All patients at the time of presentation had upper-extremity weakness and pain. Nearly all patients demonstrated T2 signal change and nodular so-called sugar-coating contrast enhancement on brachial plexus MRI. Similarly, all patients who underwent PET/MRI or PET/CT had increased FDG uptake in the involved brachial plexus. Breast cancer perineural spread has an overall poor prognosis, with 16 of 19 patients dying within 5.9 ± 3.0 years after diagnosis of perineural spread. CONCLUSIONS Perineural spread should be considered in patients with a history of breast cancer, even 10 years after primary diagnosis, especially in patients who present with arm pain, weakness, and/or sensory changes. Further diagnostic workup with electrodiagnostic studies; brachial plexus MRI, PET/CT, or PET/MRI; and possibly nerve biopsy is warranted to ensure accurate diagnosis.
Bespoke Skull Base Reconstruction Using Patient-Specific Three-Dimensional Preoperative Surgical Planner
Smith, Cody J. , Copeland, Sean R. , Deep, Nicholas L. , Nagel, Thomas H. , Barbery, Daniela , Bendok, Bernard R. , Weisskopf, Peter A., Copeland, Sean

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | March 4, 2022 | Volume: 83 | Issue: S 01 | Pages: S1-S270

10.1055/s-0042-1743605 Get It

Defining Success after Anterior Urethroplasty: An Argument for a Universal Definition and Surveillance Protocol
Anderson, Katherine T. , Vanni, Alex J. , Erickson, Bradley A. , Broghammer, Joshua A. , Buckley, Jill C. , Smith, Thomas G. , Alsikafi, Nejd F. , Elliott, Sean P. , Myers, Jeremy B. , Voelzke, Bryan B. , Breyer, Benjamin N. , Zhao, Lee C. , Rourke, Keith Francis

Mayo Clinic

Journal of Urology | March 3, 2022 | Volume: 208 | Issue: 1 | Pages: 135-143

10.1097/ju.0000000000002501 | PMID 35239415 Get It

Temporal, Location- and Symptom-Specific Likelihood of Patient-Reported Sensory Symptoms Related to Oxaliplatin-Induced Peripheral Neuropathy (OIPN) in Patients Receiving Oxaliplatin for Three Months
Zahrieh, David , Satele, Daniel , Smith, Elizabeth , Loprinzi, Charles L. , Le‐Rademacher, Jennifer , Le-Rademacher, Jennifer G , Loprinzi, Charles , Lavoie Smith, Ellen M

Mayo Clinic

Cancers | February 27, 2022 | Volume: 14 | Issue: 5 | Pages: 1212

10.3390/cancers14051212 | PMID 35267520 Get It

While oxaliplatin-induced peripheral neuropathy (OIPN) is more common and severe in patients who receive the previous standard, 6-month oxaliplatin-based treatment, we hypothesized that OIPN was still pervasive in patients who received shorter, 3-month-treatment regimens. Using six EORTC QLQ-CIPN20 questions that quantify numbness (N), tingling (T) and shooting/burning pain (P) in upper/lower distal extremities, our aim is to quantify patient-reported responses over 3 months (6 cycles) of oxaliplatin regarding symptom-specific timing, location and severity. For each question, patients were asked how each of the sensory symptoms had affected them during the preceding week, with 1 = “Not at all”, 2 = “A little”, 3 = “Quite a bit” and 4 = “Very much”. The proportional odds model for the cumulative log odds of response that allowed symptom-specific patient heterogeneity to be obtained was applied to a pooled dataset from the placebo arms of two multisite OIPN prevention trials and fit separately to the upper/lower distal extremities. For each symptom, we report the cycle-specific marginal probabilities for each response. In 141 patients, substantial patient heterogeneity in the likelihood, at a given cycle, of a more severe response for a symptom was present. Distinct patterns in the probabilities for each response over time for N and T were observed between the upper/lower distal extremities, while the probabilities of a response >1 for P was largely negligible in both locations. Despite the decrease in exposure to oxaliplatin from 6 to 3 months, OIPN was still pervasive with patients experiencing considerable N and T in the fingers (or hands) and toes (or feet).
One-Year Prospective Association of BMI with Later Cognitive Development in Preschoolers
Hansen, Carina , Smith, Latasha M. , Lynch, Brian , Miccoli, Antonela , Romanowicz, Magdalena , Toussaint, Loren , Smith, Latasha , Lynch, Brian A , Toussaint, Loren L , Hansen, Carina K

Mayo Clinic

Brain Sciences | February 27, 2022 | Volume: 12 | Issue: 3 | Pages: 320

10.3390/brainsci12030320 | PMID 35326277 Get It

This study examined the prospective relationships between preschoolers’ body mass index (BMI) and cognitive development. BMI, cognitive (i.e., Brigance), sex, and age data were collected from seven cohorts of children attending Head Start from 2012 to 2018. Children (N = 324) with two years of complete data were included. After controlling for the first year cognitive development scores, age, gender, and the cohort, the BMI was predictive of lower cognitive development scores in year two (B = −0.06, β = −0.14, t = −3.19, p = 0.002). Female sex (B = 2.69, β = 0.10, t = 2.30, p = 0.022) and older age (B = 0.02, β = 0.15, t = 3.20, p ≤ 0.001) were also shown to be statistically significant predictors of improved year two cognitive scores. The initial BMI scores were associated with poorer one year cognitive development scores in this sample of preschool children. Excessive body mass may contribute to numerous biological, psychological, and social factors that inhibit children with obesity from reaching their full cognitive potential, during a time in which brain development and cognitive skills development are at critical points of growth. Early childhood obesity interventions may have positive consequences for cognitive development, but additional prospective studies are needed to confirm these results.
Influence of locomotor muscle group III/IV afferents on cardiovascular and ventilatory responses in human heart failure during submaximal exercise
Smith, Joshua R. , Joyner, Michael J. , Keller‐Ross, Manda L. , Iterson, Erik H. Van , Olson, Thomas P. , Curry, Timothy B. , Van Iterson, Erik H , Smith, Joshua R , Joyner, Michael J , Keller-Ross, Manda , Borlaug, Barry A.

Mayo Clinic

Journal of Applied Physiology | February 24, 2022 | Volume: 132 | Issue: 4 | Pages: 903-914

10.1152/japplphysiol.00371.2021 | PMID 35201931 Get It

Patients with HFrEF exhibit severe exercise intolerance. One of the primary peripheral mechanisms contributing to exercise intolerance in patients with HFrEF is locomotor muscle group III/IV afferent feedback. However, it is unknown whether these afferents impact the central and peripheral responses during submaximal cycling exercise. Herein, we demonstrate that inhibition of locomotor muscle group III/IV afferent feedback elicited increases in stroke volume during submaximal exercise in HFrEF, but not in healthy controls.